Difference between revisions of "Colon cancer"
Line 38: | Line 38: | ||
====References==== | ====References==== | ||
# Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005 Jun 30;352(26):2696-704. [http://www.nejm.org/doi/full/10.1056/NEJMoa043116 link to original article] '''(contains protocol)''' [http://www.ncbi.nlm.nih.gov/pubmed/15987918 PubMed] | # Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005 Jun 30;352(26):2696-704. [http://www.nejm.org/doi/full/10.1056/NEJMoa043116 link to original article] '''(contains protocol)''' [http://www.ncbi.nlm.nih.gov/pubmed/15987918 PubMed] | ||
+ | |||
+ | ===CapeOx (XELOX)=== | ||
+ | CapeOX: '''<u>Cape</u>'''citabine, '''<u>OX</u>'''aliplatin <br> | ||
+ | XELOX: '''<u>XEL</u>'''oda, '''<u>OX</u>'''aliplatin | ||
+ | |||
+ | ====Regimen==== | ||
+ | *[[Capecitabine (Xeloda)]] 1000 mg/m2 PO BID days 1-14 | ||
+ | *[[Oxaliplatin (Eloxatin)]] 130 mg/m2 IV over 2 hours day 1 | ||
+ | |||
+ | '''21-day cycles x 8 cycles''' | ||
+ | |||
+ | ====References==== | ||
+ | # Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzén F, Haller DG. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007 Jan 1;25(1):102-9. [http://jco.ascopubs.org/content/25/1/102.long link to original article] '''(contains protocol)''' [http://www.ncbi.nlm.nih.gov/pubmed/17194911 PubMed] | ||
+ | # Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008 Apr 20;26(12):2006-12. [http://jco.ascopubs.org/content/26/12/2006.long link to original article] '''(contains protocol)''' [http://www.ncbi.nlm.nih.gov/pubmed/18421053 PubMed] | ||
===FLOX=== | ===FLOX=== | ||
Line 95: | Line 109: | ||
====References==== | ====References==== | ||
# Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 2006 May 1;24(13):2059-64. [http://jco.ascopubs.org/content/24/13/2059.long link to original article] '''(contains protocol)''' [http://www.ncbi.nlm.nih.gov/pubmed/16648506 PubMed] | # Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 2006 May 1;24(13):2059-64. [http://jco.ascopubs.org/content/24/13/2059.long link to original article] '''(contains protocol)''' [http://www.ncbi.nlm.nih.gov/pubmed/16648506 PubMed] | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
==Advanced or metastatic disease== | ==Advanced or metastatic disease== | ||
Line 142: | Line 144: | ||
====References==== | ====References==== | ||
− | === | + | ===CapeOx (XELOX)=== |
− | CapeOX: '''<u>Cape</u>'''citabine, '''<u>OX</u>'''aliplatin | + | CapeOX: '''<u>Cape</u>'''citabine, '''<u>OX</u>'''aliplatin <br> |
+ | XELOX: '''<u>XEL</u>'''oda, '''<u>OX</u>'''aliplatin | ||
====Regimen==== | ====Regimen==== |
Revision as of 21:34, 19 February 2012
Adjuvant therapy
5-FU & low-dose Leucovorin (Mayo Clinic regimen/LDLV)
Regimen
- Folinic acid (Leucovorin) 20 mg/m2 IV push before 5-FU days 1-5
- Fluorouracil (5-FU) 425 mg/m2 IV push days 1-5
Two different schedules have been used:
- 4-week cycles x 3 cycles, then 5-week cycles x 3 cycles
- 4-week cycles x 6 cycles
References
- O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997 Jan;15(1):246-50. link to original article (contains protocol) PubMed
- Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005 Jun 30;352(26):2696-704. link to original article (contains protocol) PubMed
- Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, Mayer RJ. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005 Dec 1;23(34):8671-8. link to original article (contains protocol) PubMed
- Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzén F, Haller DG. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007 Jan 1;25(1):102-9. link to original article (contains protocol) PubMed
5-FU & high-dose Leucovorin (Roswell Park regimen/HDLV)
Regimen
- Folinic acid (Leucovorin) 500 mg/m2 IV over 2 hours weekly x 6 weeks
- Fluorouracil (5-FU) 500 mg/m2 IV push 1 hour after start of leucovorin weekly x 6 weeks
8-week cycles x 4 cycles
References
- Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, Mayer RJ. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005 Dec 1;23(34):8671-8. link to original article (contains protocol) PubMed
- Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 2006 May 1;24(13):2059-64. link to original article (contains protocol) PubMed
- Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzén F, Haller DG. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007 Jan 1;25(1):102-9. link to original article (contains protocol) PubMed
Capecitabine (Xeloda)
Regimen
- Capecitabine (Xeloda) 1250 mg/m2 PO BID days 1-14
21-day cycles x 8 cycles
References
- Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005 Jun 30;352(26):2696-704. link to original article (contains protocol) PubMed
CapeOx (XELOX)
CapeOX: Capecitabine, OXaliplatin
XELOX: XELoda, OXaliplatin
Regimen
- Capecitabine (Xeloda) 1000 mg/m2 PO BID days 1-14
- Oxaliplatin (Eloxatin) 130 mg/m2 IV over 2 hours day 1
21-day cycles x 8 cycles
References
- Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzén F, Haller DG. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007 Jan 1;25(1):102-9. link to original article (contains protocol) PubMed
- Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008 Apr 20;26(12):2006-12. link to original article (contains protocol) PubMed
FLOX
Regimen
- Fluorouracil (5-FU) 500 mg/m2 IV bolus 1 hour after start of leucovorin weekly x 6 weeks
- Folinic acid (Leucovorin) 500 mg/m2 IV over 2 hours weekly x 6 weeks
- Oxaliplatin (Eloxatin) 85 mg/m2 IV over 2 hours on weeks 1, 3, 5; given prior to 5-FU and leucovorin
8-week cycles x 3 cycles
References
- Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007 Jun 1;25(16):2198-204. Epub 2007 Apr 30. link to original article (contains protocol) PubMed
FOLFOX 4
Regimen
- Fluorouracil (5-FU) 400 mg/m2 IV bolus, then 600 mg/m2/day IV continuous infusion over 22 hours; both bolus and continuous infusion given on days 1 & 2
- Folinic acid (Leucovorin) 200 mg/m2 IV over 2 hours before 5-FU on days 1 and 2
- Oxaliplatin (Eloxatin) 85 mg/m2 in 250 mL of 5% dextrose IV over 2 hours concurrent with leucovorin day 1
14-day cycles x 12 cycles
References
- de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000 Aug;18(16):2938-47. link to original article (contains protocol) PubMed
- André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004 Jun 3;350(23):2343-51. link to original article (contains protocol) PubMed
- Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006 Sep 1;24(25):4085-91. link to original article PubMed
- Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008 Apr 20;26(12):2006-12. link to original article PubMed
mFOLFOX 6
Regimen
- Fluorouracil (5-FU) 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day IV continuous infusion over 46-48 hours
- Folinic acid (Leucovorin) 400 mg/m2 IV over 2 hours day 1
- Oxaliplatin (Eloxatin) 85 mg/m2 IV over 2 hours day 1
14-day cycles x 12 cycles
References
- Kojima S, Ina K, Futamura Y, Ito Y, Hibi S, Nagaoka M, Yuasa S, Kawai M, Nagao S, Kataoka T. A phase I study of modified FOLFOX 6 therapy for advanced colorectal cancer. Gan To Kagaku Ryoho. 2007 Feb;34(2):203-6. link to original article (Japanese) PubMed
FULV
Regimen
- Fluorouracil (5-FU) 500 mg/m2 IV bolus 1 hour after start of leucovorin weekly x 6
- Folinic acid (Leucovorin) 500 mg/m2 IV over 2 hours weekly x 6
8-week cycles x 3 cycles
References
- Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007 Jun 1;25(16):2198-204. Epub 2007 Apr 30. link to original article (contains protocol) PubMed
UFT & leucovorin
Regimen
- Uracil-tegafur (UFT) 100 mg/m2 PO Q8H (total dose of 300 mg/m2/day) x 4 weeks
- Folinic acid (Leucovorin) 30 mg PO Q8H (total dose of 90 mg/day) x 4 weeks
- No food for 1 hour before and after each dose of medication.
5-week cycles x 5 cycles
References
- Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 2006 May 1;24(13):2059-64. link to original article (contains protocol) PubMed
Advanced or metastatic disease
mFOLFOX 6
Regimen
- Fluorouracil (5-FU) 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day IV continuous infusion over 46-48 hours
- Folinic acid (Leucovorin) 400 mg/m2 IV over 2 hours day 1
- Oxaliplatin (Eloxatin) 85 mg/m2 IV over 2 hours day 1
14-day cycles
References
- Kojima S, Ina K, Futamura Y, Ito Y, Hibi S, Nagaoka M, Yuasa S, Kawai M, Nagao S, Kataoka T. A phase I study of modified FOLFOX 6 therapy for advanced colorectal cancer. Gan To Kagaku Ryoho. 2007 Feb;34(2):203-6. link to original article (Japanese) PubMed
mFOLFOX 6 & Bevacizumab (Avastin)
Regimen
- Fluorouracil (5-FU) 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day IV continuous infusion over 46-48 hours
- Folinic acid (Leucovorin) 400 mg/m2 IV over 2 hours day 1
- Oxaliplatin (Eloxatin) 85 mg/m2 IV over 2 hours day 1
- Bevacizumab (Avastin) 5 mg/kg IV day 1
14-day cycles
References
mFOLFOX 6 & Panitumumab (Vectibix)
Regimen
- Fluorouracil (5-FU) 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day IV continuous infusion over 46-48 hours
- Folinic acid (Leucovorin) 400 mg/m2 IV over 2 hours day 1
- Oxaliplatin (Eloxatin) 85 mg/m2 IV over 2 hours day 1
- Panitumumab (Vectibix) 6 mg/kg IV over 60 minutes day 1
14-day cycles
References
CapeOx (XELOX)
CapeOX: Capecitabine, OXaliplatin
XELOX: XELoda, OXaliplatin
Regimen
- Capecitabine (Xeloda) 850-1000 (however, lower dosages often used) mg/m2 PO BID on days 1-14
- Oxaliplatin (Eloxatin) 130 mg/m2 IV over 2 hours on day 1
21-day cycles
References
CapeOX & Bevacizumab (Avastin)
CapeOX: Capecitabine, OXaliplatin
Regimen
- Capecitabine (Xeloda) 850-1000 (however, lower dosages often used) mg/m2 PO BID on days 1-14
- Oxaliplatin (Eloxatin) 130 mg/m2 IV over 2 hours on day 1
- Bevacizumab (Avastin) 7.5 mg/kg IV over 15 minutes on day 1
21-day cycles
References
FOLFIRI
Regimen
- Fluorouracil (5-FU) 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day IV continuous infusion over 46-48 hours
- Folinic acid (Leucovorin) 400 mg/m2 IV over a duration that matches irinotecan infusion day 1
- Irinotecan (Camptosar) 180 mg/m2 IV over 30-90 minutes day 1
14-day cycles
References
FOLFIRI & Bevacizumab (Avastin)
Regimen
- Fluorouracil (5-FU) 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day IV continuous infusion over 46-48 hours
- Folinic acid (Leucovorin) 400 mg/m2 IV over a duration that matches irinotecan infusion day 1
- Irinotecan (Camptosar) 180 mg/m2 IV over 30-90 minutes day 1
- Bevacizumab (Avastin) 5 mg/kg IV day 1
14-day cycles
References
FOLFIRI & Cetuximab (Erbitux)
Regimen
- Fluorouracil (5-FU) 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day IV continuous infusion over 46-48 hours
- Folinic acid (Leucovorin) 400 mg/m2 IV over a duration that matches irinotecan infusion day 1
- Irinotecan (Camptosar) 180 mg/m2 IV over 30-90 minutes day 1
- EITHER Cetuximab (Erbitux) 400 mg/m2 IV over 2 hours on cycle 1 day 1, then 250 mg/m2 IV over 60 minutes on day 8 of cycle 1; then on subsequent cycles, Cetuximab (Erbitux) 250 mg/m2 IV over 60 minutes on days 1 & 8
- OR Cetuximab (Erbitux) 500 mg/m2 IV over 2 hours on day 1
14-day cycles
References
FOLFIRI & Panitumumab (Vectibix)
Regimen
- Fluorouracil (5-FU) 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day IV continuous infusion over 46-48 hours
- Folinic acid (Leucovorin) 400 mg/m2 IV over a duration that matches irinotecan infusion day 1
- Irinotecan (Camptosar) 180 mg/m2 IV over 30-90 minutes day 1
- Panitumumab (Vectibix) 6 mg/kg IV over 60 minutes day 1
14-day cycles
References
Capecitabine (Xeloda)
Regimen
- Capecitabine (Xeloda) 850-1250 mg/m2 PO BID days 1-14
21-day cycles
References
Capecitabine (Xeloda) & Bevacizumab (Avastin)
Regimen
- Capecitabine (Xeloda) 850-1250 mg/m2 PO BID days 1-14
- Bevacizumab (Avastin) 7.5 mg/kg IV over 15 minutes on day 1
21-day cycles
References
Bolus 5-FU & Leucovorin (Roswell Park regimen/HDLV)
Regimen
- Folinic acid (Leucovorin) 500 mg/m2 IV over 2 hours weekly x 6 weeks
- Fluorouracil (5-FU) 500 mg/m2 IV push 1 hour after start of leucovorin weekly x 6 weeks
8-week cycles
References
Infusional 5-FU & Leucovorin (sLV5FU2)
Regimen
- Folinic acid (Leucovorin) 400 mg/m2 IV over 2 hours day 1 (administer first)
- Fluorouracil (5-FU) 400 mg/m2 IV bolus after leucovorin, then 1200 mg/m2/day IV continuous infusion over 46-48 hours
14-day cycles
Alternate schedule #1:
- Folinic acid (Leucovorin) 20 mg/m2 IV over 2 hours day 1 (administer first)
- Fluorouracil (5-FU) 500 mg/m2 IV bolus 1 hour after start of leucovorin
7-day cycles
Alternate schedule #2:
- Folinic acid (Leucovorin) 500 mg/m2 IV day 1 (administer first)
- Fluorouracil (5-FU) 2600 mg/m2 IV over 24 hours
7-day cycles
References
IROX
Regimen
- Oxaliplatin (Eloxatin) 85 mg/m2 IV over 2 hours on day 1 (administer first)
- Irinotecan (Camptosar) 200 mg/m2 IV over 30-90 minutes day 1 (administer second)
21-day cycles
References
FOLFOXIRI
Regimen
- Fluorouracil (5-FU) 3200 mg/m2 (total dose) IV over 48 hours on days 1-2
- Folinic acid (Leucovorin) 400 mg/m2 IV day 1
- Oxaliplatin (Eloxatin) 85 mg/m2 IV day 1
- Irinotecan (Camptosar) 165 mg/m2 IV day 1
14-day cycles
References
Irinotecan (Camptosar)
Regimen
- Irinotecan (Camptosar) 125 mg/m2 IV over 30-90 minutes on days 1 & 8
21-day cycles
Alternate schedule:
- Irinotecan (Camptosar) 300-350 mg/m2 IV over 30-90 minutes on day 1
21-day cycles
References
Cetuximab (Erbitux) & Irinotecan (Camptosar)
Regimen
- Cetuximab (Erbitux) 400 mg/m2 IV over 2 hours on cycle 1 day 1, then 250 mg/m2 IV over 60 minutes on days 8 & 15 of cycle 1; then on subsequent cycles, Cetuximab (Erbitux) 250 mg/m2 IV over 60 minutes on days 1, 8, 15
- EITHER Irinotecan (Camptosar) 300-350 mg/m2 IV over 30-90 minutes on day 1
- OR Irinotecan (Camptosar) 125 mg/m2 IV over 30-90 minutes on days 1 & 8
21-day cycles
Alternate schedule:
- Cetuximab (Erbitux) 500 mg/m2 IV over 2 hours on day 1
- Irinotecan (Camptosar) 180 mg/m2 IV over 30-90 minutes day 1
14-day cycles
References
Cetuximab (Erbitux)
Regimen
- Cetuximab (Erbitux) 400 mg/m2 IV over 2 hours on cycle 1 day 1, then 250 mg/m2 IV over 60 minutes on days 8 of cycle 1; then on subsequent cycles, Cetuximab (Erbitux) 250 mg/m2 IV over 60 minutes on days 1 & 8
14-day cycles
Alternate schedule:
- Cetuximab (Erbitux) 500 mg/m2 IV over 2 hours on day 1
14-day cycles
References
Panitumumab (Vectibix)
Regimen
- Panitumumab (Vectibix) 6 mg/kg IV over 60 minutes day 1
14-day cycles